PDF
ePub
Citation
Print
REFERENCES
1. Macchioni P, Boiardi L, Catanoso M, Pulsatelli L, Pipitone N, Meliconi R, et al. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum. 2013; 43:113–8.
2. Ogrendik M. Effects of clarithromycin in patients with active rheumatoid arthritis. Curr Med Res Opin. 2007; 23:515–22.
3. Ohe M, Bohgaki T. Successful treatment with clarithromycin for patients with polymyalgia rheumatica. Korean J Intern Med. 2014; 29:539–41.
4. Ohe M. Add-on clarithromycin and tacrolimus treatment for rheumatoid arthritis. J Rheum Dis. 2017; 24:123–4.
5. Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis. 1979; 38:434–9.
6. Yoon KH. Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review. J Biomed Biotechnol. 2010; 2010; 686480.
7. Khan AA, Slifer TR, Araujo FG, Remington JS. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents. 1999; 11:121–32.
8. van der Geest KS, Abdulahad WH, Rutgers A, Horst G, Bijzet J, Arends S, et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology (Oxford). 2015; 54:1397–402.
9. Suzuki K, Kameda H, Amano K, Nagasawa H, Takei H, Sekiguchi N, et al. Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis. Rheumatol Int. 2009; 29:431–6.
XML Download